EUVIMEDEUVIMED entdecken
Open Access

Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses

Song Wu iD, Jianbin Li, Li Bian, Siyuan Zhang, Shaohua Zhang, Tao Wang, Zefei Jiang

Translational Breast Cancer Research · 2025-07 · 6 · 22-22

DOI: 10.21037/tbcr-25-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2025-07. Verfasst von Song Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Metastatic breast cancer (MBC)human epidermal growth factor receptor 2 (HER2)-lowprogression-free survival (PFS)real-world datatrastuzumab deruxtecan (T-DXd)

Autor:innen und Institutionen

  • Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.

ORCID-Profile: Song Wu

Zitieren

APA

Wu, S., Li, J., Bian, L., Zhang, S., Zhang, S., Wang, T., & Jiang, Z. (2025). Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses. Translational Breast Cancer Research, 6, 22-22. https://doi.org/10.21037/tbcr-25-8

Vancouver

Wu S, Li J, Bian L, Zhang S, Zhang S, Wang T, et al. Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses. Translational Breast Cancer Research. 2025;6:22-22. doi:10.21037/tbcr-25-8

BibTeX
@article{Wu2025,
  author = {Wu, Song and Li, Jianbin and Bian, Li and Zhang, Siyuan and Zhang, Shaohua and Wang, Tao and Jiang, Zefei},
  title = {Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses},
  journal = {Translational Breast Cancer Research},
  year = {2025},
  volume = {6},
  pages = {22--22},
  doi = {10.21037/tbcr-25-8}
}
Kostenlos starten →